Mycotoxin Contamination in Herbal Ingredients: What EU Regulations Actually Require

Three incoming lots of valerian root. Supplier CoAs for all three listed mycotoxins as “not detected.” Independent testing on arrival returned aflatoxin B1 values between 6 and 12 µg/kg on each lot — every one of them above the 5 µg/kg limit set under EU Regulation 1881/2006.

That’s not an isolated scenario. It’s the pattern that emerges, with striking regularity, when European supplement and botanical brands move from CoA reliance to verified incoming testing for the first time.

Mycotoxin contamination in herbal ingredients is one of the most consistently underestimated compliance risks in the European supplement sector. Part of the reason is structural: the EU harmonised maximum limits for mycotoxins in herbs and botanicals under Regulation 1881/2006 — but enforcement lands on the finished product manufacturer or EU importer, not on the overseas supplier. The CoA your supplier sends is, at most, a data point. It is not a compliance defence.

Where Mycotoxin Contamination Actually Comes From

Mycotoxins are secondary metabolites produced by filamentous fungi — predominantly Aspergillus, Fusarium, and Penicillium species. In herbal raw materials, contamination can occur at three distinct stages: in the field before harvest, during drying and initial processing, and during storage and transit across often-long supply chains.

Botanicals from South Asia, East Africa, and Southeast Asia account for the majority of EU RASFF (Rapid Alert System for Food and Feed) notifications related to mycotoxin exceedances in herbal materials. Turmeric, black pepper, ginger, liquorice root, fennel seed, and dried chilli are among the most frequently flagged commodities. But temperate-climate herbs aren’t immune. Valerian, St. John’s Wort, and chamomile can accumulate ochratoxin A under poor storage conditions, even when the material originated entirely within Europe.

The critical point here is that mycotoxin contamination is not visible, not detectable by smell, and not eliminated by normal formulation processing. You cannot inspect your way out of this problem. Standard manufacturing steps — blending, granulation, encapsulation, tableting — do not reduce mycotoxin levels meaningfully. Once contaminated botanical material enters your supply chain, the contamination follows the finished product all the way to the consumer.

The EU Regulatory Framework — What the Law Actually Says

Commission Regulation (EC) No 1881/2006 is the foundational instrument for maximum mycotoxin levels in foodstuffs, most recently consolidated and succeeded by Commission Regulation (EU) 2023/915 of 28 April 2023. For herbs and spices — the classification under which most herbal raw materials enter the EU — the applicable limits are:

• Aflatoxin B1: 5 µg/kg maximum
• Total aflatoxins (B1 + B2 + G1 + G2): 10 µg/kg maximum
• Ochratoxin A: 20 µg/kg maximum for key herbal spices including turmeric (Curcuma longa), ginger (Zingiber officinale), black pepper (Piper nigrum), nutmeg (Myristica fragrans), and paprika and chilli (Capsicum spp.)

Where a herbal ingredient is destined for use in a food supplement — not simply as a culinary spice — the same limits apply. The European Food Safety Authority’s CONTAM Panel has confirmed the relevance of these limits to food supplement applications, and member state enforcement bodies in France (DGCCRF), Germany (LGL, LAVES), and Italy (NAS Carabinieri) have aligned their inspection practice accordingly.

The compliance responsibility sits unambiguously with the EU-based manufacturer or the responsible person marketing the finished product. That means if you’re sourcing turmeric extract from an Indian supplier and encapsulating it at your facility in Lyon or Hamburg, the aflatoxin and ochratoxin A limits are yours to verify — not your supplier’s to promise.

Sampling methodology matters just as much as the analytical result. Commission Regulation (EC) No 401/2006 governs the methods of sampling and analysis for official mycotoxin control, specifying minimum lot sizes, the number of incremental samples required, aggregate sample weights, and analytical method requirements. A single 5-gram sub-sample dispatched to a general food laboratory is not a compliant sampling event for a 500-kg incoming lot of botanical material. Regulators know the difference, and documented non-compliance with sampling requirements can invalidate otherwise acceptable results.

Why Supplier CoAs Are Not a Compliance Defence

This deserves to be stated plainly, because it is the most common misconception we encounter among European supplement brands.

A CoA from your overseas ingredient supplier is a commercial document. It reflects a test conducted by the supplier, on the supplier’s sample, using the supplier’s chosen method, at whatever detection limit the supplier’s laboratory equipment can achieve. When EU authorities test your finished product or incoming raw material and find an exceedance, a CoA showing “not detected” provides no regulatory protection. It may be useful evidence in a civil claim against your supplier. It does not constitute a GMP-compliant quality assurance programme.

The analytical method matters more than most procurement teams realise. Detecting mycotoxins reliably in complex botanical matrices requires appropriate cleanup — typically immunoaffinity column (IAC) purification — before chromatographic analysis. The EU reference methods under Regulation 401/2006 specify HPLC with fluorescence detection (HPLC-FLD) as the confirmatory approach for aflatoxins. LC-MS/MS methods are increasingly accepted and are now preferred for multi-mycotoxin screening, given their sensitivity and the ability to detect a broad panel of toxins in a single analytical run.

Many supplier laboratories use ELISA-based screening for speed and cost. A general ELISA test for aflatoxin B1 typically has a detection limit in the 0.5–2 µg/kg range — adequate for flagging gross contamination, but unreliable when you’re testing close to the regulatory limit of 5 µg/kg. It is entirely possible for a material to screen as “not detected” by ELISA and still return a confirmatory HPLC-FLD result above the limit. The CoA your supplier attaches to the shipment may be technically accurate for the method used, and still be misleading in a compliance context.

The European Pharmacopoeia addresses testing requirements directly. General Chapter 2.8.18 covers aflatoxin B1 in herbal drugs using an HPLC method with post-column derivatisation. General Chapter 2.8.22 covers ochratoxin A. Where your herbal ingredient has a Ph.Eur. monograph — and a significant number do — these general chapter requirements are referenced within the monograph and form part of the pharmacopoeial specification. Using a non-equivalent method without documented validation is a GMP deficiency that a competent auditor will identify.

Building an Incoming Testing Programme That Holds Up Under Scrutiny

The practical question is what a defensible incoming testing programme looks like for a European supplement or botanical cosmetic manufacturer. Based on the regulatory framework and what member state inspectorates are actually asking for, these are the components that matter:

Risk-tier your suppliers and commodities. Not every botanical requires the same testing frequency or verification depth. High-risk commodities — those with documented RASFF histories, tropical origin, or complex multi-stage processing chains — warrant verified third-party testing on every incoming lot. Lower-risk botanicals from established European suppliers with audited quality systems can reasonably be tested on a rotation, provided the rationale is documented. The tiering decision itself needs to sit in your quality system with a justification — inspectors look for exactly this.

Specify the analytical method, not just the analyte. Your incoming material specifications should state the required method, the detection limit, and the sampling protocol. “Aflatoxins: compliant with EU limits” is not a specification. “Aflatoxin B1: ≤5 µg/kg, tested by HPLC-FLD per Commission Regulation (EC) No 401/2006 sampling protocol, minimum aggregate sample 50 g” is. That level of specificity protects you and creates an enforceable commitment for your supplier.

Use a laboratory with demonstrated herbal matrix competence. Testing mycotoxins in a botanical extract or dried herb powder is analytically more demanding than testing a grain commodity. Matrix effects are significant, particularly in extracts with high polyphenol, chlorophyll, or pigment content. Look for ISO 17025 accreditation with a stated scope that explicitly covers herbal and botanical matrices — not just general food mycotoxin testing. This distinction is more meaningful than many quality managers appreciate when selecting a contract laboratory.

Retain testing records within your technical documentation. Mycotoxin testing results for herbal raw materials are part of the raw material documentation that informs your safety assessment. For food supplements, the responsible person must be able to produce these records on request. For herbal cosmetic products incorporating botanical extracts, they support the Cosmetic Product Safety Report by demonstrating that known contaminant risks in botanical ingredients have been characterised and controlled.

Don’t plan on decontamination as a fallback. Commission Regulation (EU) 2015/786 specifies the criteria for decontamination processes applied to foodstuffs contaminated with mycotoxins, and the framework is restrictive. Many physical and chemical treatment approaches are either prohibited, restricted to specific commodity types, or require specific authorisation for each use. If an incoming lot fails, your realistic options are rejection and return to supplier, or supervised destruction. Planning to treat your way out of a mycotoxin exceedance is not a viable compliance strategy.

The herbal and supplement sector in Europe is genuinely underserved for specialised mycotoxin testing competence. Most accredited food laboratories handle grain and cereal commodities well; the specific expertise required for botanical and extract matrices is considerably less common. That gap creates real compliance risk — but for brands that build testing programmes reflecting what the regulations actually require, it also creates a meaningful competitive advantage. Your quality documentation tells auditors, regulators, and buyers exactly what rigour looks like when applied properly.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry. Contact us

Related from our network

• Multi-mycotoxin and heavy metal testing for botanical raw materials — Qalitex Laboratories offers ISO 17025-accredited herbal ingredient testing including aflatoxin, ochratoxin A, and multi-mycotoxin panels for North American market compliance
• NHP raw material testing for Health Canada compliance — Androxa provides Canadian laboratory services for European brands entering the NHP market, including mycotoxin and microbial testing on herbal and supplement ingredients